Investor · 1 deal
Every published round M.H. Carnegie & Co took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| EBR Systems | Unnamed stage | Nov 2021 | $30m+ | Participant | Brandon BioCatalyst, Brandon Capital, Brandon Capital portfolio |
Companies M.H. Carnegie & Co has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| EBR Systems | Developer of a left ventricular cardiac resynchronisation device | Nov 2021 | 1 | 0 |
Fund closes reported for M.H. Carnegie & Co, as distinct from the investments it has made.
Companies M.H. Carnegie & Co has backed that another company then bought. An exit for the holding, not a deal M.H. Carnegie & Co did.
Stories naming M.H. Carnegie & Co. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Cardiac pacing company EBR Systems says its SOLVE-CRT trial hit its safety and efficacy goals early, keeping a 2024 US approval bid on course; the article also recalls its 2021 ASX listing.
US-based leadless pacemaker maker EBR Systems has listed on the ASX, spurning US SPAC offers thanks to its local investor base; Blackbird's earlier investment in Vexev is also noted.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio